Syndax Pharmaceuticals, Inc. Subsidiaries
Every subsidiary the company listed in Exhibit 21 of its annual reports, newest list first (4 lists). Names and jurisdictions are as filed.
- 2026-02-26: Subsidiary Syndax Europe B.V.; Jurisdiction Netherlands.
- 2025-03-03: Subsidiary Syndax Securities Corporation; Jurisdiction Massachusetts.
- 2025-03-03: Subsidiary Syndax Europe B.V.; Jurisdiction Netherlands.
- 2023-02-28: Subsidiary Syndax Securities Corporation; Jurisdiction Massachusetts.
| Annual report filed | Subsidiary | Jurisdiction |
|---|---|---|
| 2026-02-26 | Syndax Europe B.V. | Netherlands |
| 2025-03-03 | Syndax Securities Corporation | Massachusetts |
| 2025-03-03 | Syndax Europe B.V. | Netherlands |
| 2023-02-28 | Syndax Securities Corporation | Massachusetts |
| 2023-02-28 | Syndax Limited | United Kingdom |
| 2023-02-28 | Syndax Europe B.V. | Netherlands |
| 2022-03-01 | NameJurisdiction of Incorporation | |
| 2022-03-01 | Syndax Pharmaceuticals, IncDelaware | |
| 2022-03-01 | Syndax United KingdomUnited Kingdom | |
| 2022-03-01 | Syndax Europe B.V.The Netherlands |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |